Evidence map›Paper›PMID 35951081›Full record

ArticleApplied microbiology and biotechnology2022

A potent virucidal activity of functionalized TiO

Gabriela León-Gutiérrez, James Edward Elste, Carlos Cabello-Gutiérrez, Cesar Millán-Pacheco, Mario H Martínez-Gómez, Rafael Mejía-Alvarez, Vaibhav Tiwari, Armando Mejía

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Anti-Infective Screening of Selected Nine Cannabinoids AgainstCurrent issues in molecular biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Metallo-antiviral aspirants:European journal of medicinal chemistry reports · 2023
    Review
  8. Review
  9. Peptides for Coating TiOInternational journal of molecular sciences · 2022
    Article
  10. Nanoparticles for Antimicrobial Agents Delivery-An Up-to-Date Review.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Gabriela León-GutiérrezDepartamento de Biotecnología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de Mexico, Mexico.ORCID http://orcid.org/0000-0001-5934-0235
James Edward ElsteDepartment of Microbiology and Immunology, Midwestern University, Downers Grove, IL, USA.ORCID http://orcid.org/0000-0002-7970-0485
Carlos Cabello-GutiérrezDepartamento de Virología e Investigación en Micología, Instituto Nacional de Enfermedades Respiratorias, Ciudad de Mexico, Mexico.ORCID http://orcid.org/0000-0002-3192-8915
Cesar Millán-PachecoFacultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.ORCID http://orcid.org/0000-0001-5180-6504
Mario H Martínez-GómezDepartamento de Biotecnología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de Mexico, Mexico.ORCID http://orcid.org/0000-0001-6155-6465
Rafael Mejía-AlvarezDepartment of Physiology, College of Graduate Studies, Midwestern University, Downers Grove, IL, USA.ORCID http://orcid.org/0000-0002-1961-9538
Vaibhav TiwariDepartment of Microbiology and Immunology, Midwestern University, Downers Grove, IL, USA.ORCID http://orcid.org/0000-0002-8798-6815
Armando MejíaDepartamento de Biotecnología, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de Mexico, Mexico. ama@xanum.uam.mx.ORCID http://orcid.org/0000-0001-9857-347X
Midwestern University · USUniversidad Autónoma Metropolitana · MXInstituto Nacional de Enfermedades Respiratorias · MXUniversidad Autónoma del Estado de Morelos · MX

Funding

Consejo Nacional de Ciencia y Tecnología Conacyt-LANCAD-UNAM-DGTIC-110LANCAD-CONACYT Yoltla at LSVP UAMMidwestern University Startup fundsUniversidad Autónoma Metropolitana s/nUniversidad Nacional Autónoma de México SC16-1-IR-120-UNAM
6 · The paper itself

Abstract

The coronavirus SARS-CoV-2 has caused a pandemic with > 550 millions of cases and > 6 millions of deaths worldwide. Medical management of COVID-19 relies on supportive care as no specific targeted therapies are available yet. Given its devastating effects on the economy and mental health, it is imperative to develop novel antivirals. An ideal candidate will be an agent that blocks the early events of viral attachment and cell entry, thereby preventing viral infection and spread. This work reports functionalized titanium dioxide (TiO

Indexed as

COVID-19 Drug TreatmentNanoparticlesAntiviral AgentsFlavonoidsHumansMolecular Docking SimulationSARS-CoV-2Spike Glycoprotein, CoronavirusTitaniumAntiviral AgentsFlavonoidsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Titaniumtitanium dioxideFlavanone-7-O-glucosideHesperetin-7-rutinosideNanoparticulate compoundSARS-CoV-2 spike glycoprotein

Identifiers

PMID35951081
PMCPMC9366830
OpenAlexW4291016567

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.